Uveitis Market

Aug 05, 2020

10 likes | 61 Views

In 2017, the total prevalent cases of Uveitis in the United States were 357,791. It was found that in the United States, Acute Anterior Uveitis accounted for 43% of the total cases of Uveitis in 2017. The market size of Uveitis in the seven major markets (i.e the US, Germany, France, Italy, the UK, Spain and Japan) was found to be USD 1,045.9 Million in 2017, which is expected to increase during the forecast period. Availability of ocular inserts, orphan drug status, introduction of biologic drugs, and rich emerging pipeline with diverse ROA and MOA are some of the key factors expected to drive the Uveitis market forward in the coming years. The key players in the Uveitis market includes Aldeyra Therapeutics, Santen Pharmaceutical, Oculis, EyeGate Pharma, Novartis, Clearside Biomedical, Bristol-Myers Squibb, Sanofi, Eyevensys and many others. For more details visit: https://www.delveinsight.com/report-store/uveitis-market

DelveInsight

Download Presentation

Uveitis Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D